Read by QxMD icon Read

Pediatric Blood & Cancer

Michael V Ortiz, Shannon Fernandez-Ledon, Kavitha Ramaswamy, Christopher J Forlenza, Neerav N Shukla, Rachel Kobos, Todd E Heaton, Michael P LaQuaglia, Peter G Steinherz
From 2009 to 2018, 10 consecutive patients with Wilms tumors and bilateral nephroblastomatosis, who had completed standard therapy, were provided a maintenance chemotherapy regimen consisting of vincristine and dactinomycin every 3 months for 12 months in order to prevent an early metachronous Wilms tumor. One patient (10%) with Beckwith-Wiedemann syndrome developed a new tumor, without anaplasia. There were no significant toxicities reported during maintenance. All patients are currently alive with no evidence of disease...
October 18, 2018: Pediatric Blood & Cancer
Margaret S Robertson, Susan S Hayashi, Miranda L Camet, Kathryn Trinkaus, Jennifer Henry, Robert J Hayashi
BACKGROUND: Ototoxicity is a significant complication of cisplatin treatment. Hearing loss can be symmetric or asymmetric, and may decline after therapy. This study examined the risks of asymmetric and late-onset hearing loss (LOHL) in cisplatin-treated pediatric patients with cancer. METHODS: A retrospective review of 993 patients' medical and audiological charts from August 1990 to March 2015 was conducted using stringent criteria to characterize patients with asymmetric hearing loss (AHL) or LOHL...
October 18, 2018: Pediatric Blood & Cancer
Ashleigh Kussman, David Shyr, Gregory Hale, Benjamin Oshrine, Aleksandra Petrovic
Relapse remains the most common cause of treatment failure after hematopoietic cell transplantation for acute myeloid leukemia. Inability to achieve hematologic complete remission has been a barrier to transplant for patients with refractory disease. We describe six children with refractory myeloid disease undergoing transplant in chemotherapy-induced aplasia, as a strategy to facilitate curative therapy in refractory patients. Clofarabine- or high-dose cytarabine-based chemotherapy regimens were used to achieve marrow aplasia, followed by reduced-intensity conditioning and allogeneic transplant before hematologic recovery...
October 14, 2018: Pediatric Blood & Cancer
Meaghann S Weaver, Wendy G Lichtenthal, Kara Larson, Lori Wiener
Bereaved families fear their child being forgotten by those who knew their loved child, including their child's oncology team. Thoughtfully timed, family-centric condolences shared by pediatric oncology team members have the potential to extend our compassion and kindness toward a family during the darkness of grief. Well-intended medical teams sometimes feel "at a loss" in terms of what to say to a grieving family and how or when to say it. This paper provides a tangible overview of written or verbal condolence communication in a format that can be personalized to the provider and the patient's family...
October 14, 2018: Pediatric Blood & Cancer
Heidi V Russell
No abstract text is available yet for this article.
October 14, 2018: Pediatric Blood & Cancer
Krista McKinnon, Jennifer Jupp, Sunita Ghosh, Carol Digout, Stephanie Eason, Marcel Romanick
BACKGROUND: Chemotherapy-induced nausea and vomiting (CINV) impacts quality of life for patients. Guidelines for emetogenicity classification and prevention of CINV in children were recently published and endorsed by pediatric oncology organizations. PROCEDURE: A multicenter chart review was performed at four Canadian pediatric oncology centers examining rates of prescribing adherence to CINV guidelines between January 2012 and December 2015. Eligible patients received their first chemotherapy course of highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC)...
October 14, 2018: Pediatric Blood & Cancer
Sanne Ten Berg, Erik A H Loeffen, Marianne D van de Wetering, Daniëlle H J Martens, Carla M van Ede, Leontien C M Kremer, Wim J E Tissing
INTRODUCTION: Febrile neutropenia (FN) is a common complication of the intensive treatment strategies used in pediatric oncology. By close adherence to high-quality guidelines, which can be evaluated by indicators, the burden of FN can potentially be reduced. OBJECTIVES: The aims of this study were tripartite-(1) to develop structure, process, and outcome indicators, (2) to evaluate the implementation of the Dutch Childhood Oncology Group (DCOG) guideline on FN, and (3) to produce baseline measures on local quality of FN care (in the north of the Netherlands)...
October 14, 2018: Pediatric Blood & Cancer
Bas Vaarwerk, Reineke A Schoot, Heleen Maurice-Stam, Olga Slater, Benjamin Hartley, Peerooz Saeed, Eva Gajdosova, Michiel W van den Brekel, Alfons J M Balm, Marinka L F Hol, Stefanie van Jaarsveld, Leontien C M Kremer, Cecile M Ronckers, Henry C Mandeville, Bradley R Pieters, Mark N Gaze, Raquel Davila Fajardo, Simon D Strackee, David Dunaway, Ludi E Smeele, Julia C Chisholm, Huib N Caron, Martha A Grootenhuis, Johannes H M Merks
BACKGROUND: Head and neck rhabdomyosarcoma (HNRMS) survivors are at risk to develop adverse events (AEs). The impact of these AEs on psychosocial well-being is unclear. We aimed to assess psychosocial well-being of HNRMS survivors and examine whether psychosocial outcomes were associated with burden of therapy. PROCEDURE: Sixty-five HNRMS survivors (median follow-up: 11.5 years), treated in the Netherlands and the United Kingdom between 1990 and 2010 and alive ≥2 years after treatment visited the outpatient multidisciplinary follow-up clinic once, in which AEs were scored based on a predefined list according to the Common Terminology Criteria for Adverse Events...
October 14, 2018: Pediatric Blood & Cancer
Christopher DeRenzo, Catherine Lam, Carlos Rodriguez-Galindo, Louis Rapkin, Stephen Gottschalk, Rajkumar Venkatramani
There is no established salvage regimen for pediatric patients with relapsed nasopharyngeal carcinoma (NPC) and outcomes are dismal. We performed a multicenter retrospective review to determine outcomes after first salvage therapy for pediatric patients with relapsed NPC. Fourteen patients were treated with varied regimens. Two of the 14 patients received oxaliplatin-containing regimens and achieved a long-term complete response. Although definitive recommendations cannot be made based on outcomes for 14 patients who received varied regimens, we discuss justification for an oxaliplatin-containing regimen in combination with gemcitabine as a reasonable choice for first-line salvage therapy for pediatric patients with relapsed NPC...
October 14, 2018: Pediatric Blood & Cancer
Kristof Vandekerckhove, Kathleen De Waele, Aurelie Minne, Ilse Coomans, Katya De Groote, Joseph Panzer, Catherine Dhooge, Victoria Bordon, Daniel De Wolf, Jan Boone
BACKGROUND: Physical fitness is an important determinant of quality of life (QOL) after hematopoietic stem cell transplantation. Cardiac function can influence exercise performance. The aim of this study was to assess these factors and their interrelationship. PROCEDURE: Children underwent cardiopulmonary exercise testing (CPET) at least 1 year after hematopoietic stem cell transplantation (HSCT) and were compared with healthy controls. Systolic and diastolic heart function and left ventricle (LV) wall dimensions were measured...
October 14, 2018: Pediatric Blood & Cancer
Amy E Armstrong, David O Walterhouse, Patrick J Leavey, Jennifer Reichek, Amy L Walz
Outcome for patients with metastatic or recurrent/refractory osteosarcoma remains poor. Responses to sorafenib, a multikinase inhibitor, have been seen in recurrent/refractory osteosarcoma, although specific biomarkers of response have not been described. We report a partial response in a 7-year-old with refractory osteosarcoma treated with sorafenib 200 mg twice daily. Toxicities included Common Terminology Criteria for Adverse Events Grade 2 skin toxicities and growth suppression. After 51 months of therapy, he suffered a recurrence...
October 14, 2018: Pediatric Blood & Cancer
A S Fahy, I Kong, S Weitzman, D Dix, S Baruchel, J T Gerstle
Treatment of Hodgkin lymphoma (HL) has advanced over time, rendering a fatal disease now largely curable. Multiagent chemotherapy regimens, hematopoietic stem cell transplantation, and radiotherapy are the mainstays of care. Surgical intervention is rarely indicated other than for biopsy at diagnosis. However, for patients with recurrent relapsed HL isolated to one anatomical location, refractory to all other therapy, there may be a beneficial role for surgical excision. Herein, we report the surgical management of three relapsed patients with stage IVB HL who were refractory to multiple other therapeutic approaches, who all achieved good event-free survival after operative management...
October 8, 2018: Pediatric Blood & Cancer
Bella Shadur, Nathalie Asherie, Peter E Newburger, Polina Stepensky
Mutations in the VPS45 gene lead to a severe primary immune deficiency characterized by severe congenital neutropenia and primary myelofibrosis, leading to overwhelming infection and early death. This condition is exceedingly rare with only 16 patients previously reported, including four with successful hematopoietic stem cell transplantation. We review the pathophysiology underlying this condition and detail our approach to treatment, particularly vis-à-vis bone marrow transplantation and the challenges of transplanting into a diseased bone marrow niche...
October 7, 2018: Pediatric Blood & Cancer
Ashley Wilder Smith, Theresa Keegan, Ann Hamilton, Charles Lynch, Xiao-Cheng Wu, Stephen M Schwartz, Ikuko Kato, Rosemary Cress, Linda Harlan
Historically, adolescents and young adults (AYA) diagnosed with cancer have been an understudied population, and their unique care experiences, needs, and outcomes were not well understood. Thus, 10 years ago, the National Cancer Institute supported the fielding of the Adolescent and Young Adult Health Outcomes and Patient Experiences (AYA HOPE) study to address this gap. We recruited individuals diagnosed at ages 15 to 39 with germ cell, Hodgkin and non-Hodgkin lymphoma, acute lymphoblastic leukemia, and sarcoma from Surveillance, Epidemiology, and End Results cancer registries into the first multicenter population-based study of medical care, physical, and mental health outcomes for AYAs with cancer in the United States...
October 7, 2018: Pediatric Blood & Cancer
Ting-Chi Yeh, Der-Cherng Liang, Hsi-Che Liu, Tang-Her Jaing, Shih-Hsiang Chen, Jen-Yin Hou, Chao-Ping Yang, Ying-Jung Huang, Hsien-Wen Yao, Ting-Yu Huang, Tung-Huei Lin, Lee-Yung Shih
BACKGROUND: The leukemogenesis of T-cell acute lymphoblastic leukemia (T-ALL) involves multistep processes of genetic alterations. We aimed to determine the genetic alterations including common fusion transcripts, overexpression of T-cell transcription factor oncogenes, and deletion or mutation of targeted genes in pediatric T-ALL in Taiwan as well as their impact on outcomes in those treated with the Taiwan Pediatric Oncology Group-ALL-2002 protocol. PROCEDURE: Between 1995 and 2015, bone marrow samples obtained from 102 children aged <18 years consecutively diagnosed with T-ALL were examined...
October 2, 2018: Pediatric Blood & Cancer
Arun Gurunathan, Alexander A Boucher, Melissa Mark, Kristina M Prus, Maureen M O'Brien, Erin H Breese, Benjamin E Mizukawa, Michael J Absalon, Adam S Nelson, Michael B Jordan, Michael S Grimley, Robert B Lorsbach, Seth J Rotz, Reema Mathanda, Ashish R Kumar
Hemophagocytic lymphohistiocytosis (HLH) is characterized by dysregulated immune activation.  Primary HLH involves hereditary deficits in cytotoxic lymphocytes while secondary HLH is triggered by extrinsic factors. The HLH-2004 criteria are widely used for clinical diagnosis, yet their specificity for HLH or their ability to differentiate primary from secondary disease is unclear, potentially leading to inappropriate treatment. We describe several cases where fulfillment of HLH-2004 criteria obscured the diagnoses of underlying malignancies and delayed curative management...
October 1, 2018: Pediatric Blood & Cancer
Paola Giordano, Flavia Urbano, Giuseppe Lassandro, Francesco Paolo Bianchi, Alessandra Tolva, Paola Saracco, Giovanna Russo, Lucia Dora Notarangelo, Maria Gabelli, Simone Cesaro, Malgorzata Wasniewska, Maria Felicia Faienza
BACKGROUND: Immune thrombocytopenia (ITP) is an acquired immune-mediated disorder characterized by isolated thrombocytopenia. Pediatric ITP patients are prone to develop autoantibodies such as antithyroglobulin (TG) and antithyroperoxidase (TPO), even in the absence of clinical signs of autoimmune disease. The aim of this multicenter retrospective study was to evaluate (1) the prevalence of positivity of antithyroid antibodies (TPO and TG) in a large cohort of pediatric patients with chronic ITP; (2) the role of autoimmune thyroiditis as a prognostic factor for chronicity of ITP...
September 30, 2018: Pediatric Blood & Cancer
Volker Strenger, Harald H Kessler, Evelyn Stelzl, Stephan W Aberle, Markus Keldorfer, Klara Zach, Anna Karastaneva, Daniela Sperl, Herwig Lackner, Martin Benesch, Christian Urban, Hans Jürgen Dornbusch
BACKGROUND: Enteroviruses (EV) are a large group of Picornaviruses associated with respiratory, gastrointestinal, and neurologic symptoms in the immunocompetent host. Little is known about the epidemiologic and clinical impact in pediatric hematologic/oncologic patients. PROCEDURE: From 2001 through 2017, different clinical specimens were collected from pediatric hematologic/oncologic patients and were tested for enteroviral RNA. RESULTS: Of 13 004 specimens collected from 761 patients, 38 (0...
September 30, 2018: Pediatric Blood & Cancer
Hirotoshi Sakaguchi, Hideki Muramatsu, Daiichiro Hasegawa, Kazuko Kudo, Hiroyuki Ishida, Nao Yoshida, Katsuyoshi Koh, Maiko Noguchi, Norio Shiba, Sadao Tokimasa, Takhiro Fukuda, Hiroaki Goto, Takako Miyamura, Yozo Nakazawa, Yoshiko Hashii, Masami Inoue, Yoshiko Atsuta
BACKGROUND: Indications for hematopoietic stem cell transplantation (HSCT) have decreased with the improvement in chemotherapy for pediatric acute myeloid leukemia (AML) in the last decade. We conducted reevaluation of autologous HSCT (AHSCT) to compare myeloablative conditioning (MAC) regimens for pediatric AML without the need for consideration of toxicities caused by allogeneic immune reactions. PROCEDURE: This retrospective study analyzed the clinical outcomes of 220 children with AML who underwent consecutive AHSCT between 1989 and 2002 in Japan by the national prospective registry...
September 30, 2018: Pediatric Blood & Cancer
Hilary A Marusak, Allesandra S Iadipaolo, Shelley Paulisin, Felicity W Harper, Jeffrey W Taub, Kristopher Dulay, Farrah Elrahal, Craig Peters, Kelsey Sala-Hamrick, Laura M Crespo, Christine A Rabinak
BACKGROUND: Pediatric cancer is a life-changing, stressful experience for children and their families. Although most children adjust well, psychologically, a significant subset report posttraumatic stress symptoms (PTSS), with nearly 75% reexperiencing traumatic parts of cancer and/or its treatment. However, little research has examined the effects of pediatric cancer and related PTSS on emotional processing, and on functional properties of key emotional centers in the brain (e.g., amygdala)...
September 30, 2018: Pediatric Blood & Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"